semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson's Disease UK Parkinson's Disease Society (UKPDS) brain bank (Step 1 and 2) for PD. 2. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale. 3. On levodopa/DCI for at least one year, stable dose in past 4 weeks. 4. Currently take at least three doses of levodopa/DCI per day. 5. Predictable end of dose wearing off. 6. Able to satisfactorily complete Hauser version of a Parkinson's diary. 7. Have an average of 120 minutes of OFF time on two 24 hour diaries. 8. On a stable regimen of medications being administered within normal therapeutic limits for Parkinson's disease for at least four weeks before randomization. 9. Be at least 30 years of age  Neurosurgical treatment for PD. 2. History of psychosis. 3. Diagnosis of atypical Parkinsonism or secondary Parkinsonism variant. 4. Diagnosis of cancer within 5 years. 5. Diagnosis of clinically significant illness of any organ system. 6. Mini-mental status examination score of 25 or less. 7. Taking any excluded medications. 8. History of drug or alcohol abuse or dependence within the past two years. 9. History of seizures or neurological malignant syndrome. 10. Clinical depression. 11. Pregnant or lactating females
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson's Disease UK Parkinson's Disease Society (UKPDS) brain bank (Step 1 and 2) for PD. 2. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale. 3. On levodopa/carbidopa for at least one year, stable dose in past 4 weeks. 4. Currently take at least three doses of levodopa/carbidopa per day. 5. Predictable end of dose wearing off. 6. Able to satisfactorily complete Hauser version of a Parkinson's diary. 7. Have an average of 180 minutes of OFF time on two 24 hour diaries. 8. Be at least 30 years of age  Neurosurgical treatment for PD. 2. History of psychosis. 3. Diagnosis of atypical parkinsonism, secondary parkinsonism variant or Parkinson's plus syndromes. 4. Diagnosis of cancer within 5 years. 5. Mini-mental status examination score of 25 or less. 6. History of seizures or neurologic malignant_syndrome. 7. Clinical depression
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Parkinson's Disease UK Parkinson's Disease Society (UKPDS) brain bank (Step 1 and 2) for PD. 2. PD stages 2-4 in the OFF state for Modified Hoehn and Yahr Scale. 3. On levodopa/carbidopa for at least one year, stable dose in past 4 weeks. 4. Currently take at least three doses of levodopa/carbidopa per day. 5. Predictable end of dose wearing off. 6. Able to satisfactorily complete Hauser version of a Parkinson's diary. 7. Have an average of 180 minutes of OFF time on two 24 hour diaries. 8. Be at least 30 years of age  Neurosurgical treatment for PD. 2. History of psychosis. 3. Diagnosis of atypical parkinsonism, secondary parkinsonism variant or Parkinson's plus syndromes. 4. Diagnosis of cancer within 5 years. 5. Mini-mental status examination score of 25 or less. 6. History of seizures or neurologic malignant_syndrome
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Clinical diagnosis of Parkinson's disease  No clinical diagnosis of Parkinson's disease
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-85.0,  Parkinson's Disease With End of Dose Wearing Off Males or females 30-80 years of age (inclusive). Patients aged 81-85 years were eligible to participate if the principal investigator considered the patient to be in otherwise good health Clinical diagnosis of Parkinson's disease exhibiting two of three symptoms (rigidity, resting tremor, bradykinesia) All patients were required to have end-of dose wearing off (EODWO, re-emergence of PD symptoms at the end of at least two daily doses of levodopa during waking hours) Taking regular doses of immediate release carbidopa/levodopa  Unstable Parkinson's Disease requiring booster doses or treatment with as needed dose regimens of levodopa Female subjects who are pregnant, trying to become pregnant or nursing an infant Other protocol-defined inclusion/ applied to this study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Parkinson Disease Male or female outpatients Age >=35 years at screening Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's symptoms, i.e. resting tremor, bradykinesia and rigidity Duration of the disease of less than 3 years since diagnosis Modified Hoehn and Yahr stage <= 2.5 Patient optimized on monotherapy by levodopa or a dopamine agonist· Generally healthy and ambulatory Patient has given his informed written consent and is capable of following study procedures  Any indication of forms of parkinsonism other than PD Severe resting tremor. Presence of either dyskinesia, fluctuations, or loss of postural reflexes· Treatment with amantadine, anticholinergics, catechol-o-methyltransferase (COMT ) inhibitors, selegiline, dopamine receptor antagonists, catecholamine depleters, indirect dopamine agonists or alphamethyldopa. Electroconvulsive therapy (ECT).Use of CYP3A4 strong, and moderate inducers or inhibitors. Participation in another clinical trial with an investigational drug within two months prior to randomization Dementia, uncontrolled depression, psychotic disorder. History of substance-related disorders including alcohol or other substance use disorders Females of child bearing potential Evidence (detected by history, physical examination and/or laboratory/ECG tests) of any clinically significant or unstable medical disorder that could interfere with the patient's participation in the clinical trial; interfere with the absorption, metabolism or excretion of the study medication; or interfere with the evaluation of the study drug. Alterations of laboratory tests or ECG findings of potential clinical significance
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Parkinson Disease Male or female outpatients Age >=35 years at screening.· Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's symptoms, i.e. resting tremor, bradykinesia and rigidity Duration of the disease of less than 3 years since diagnosis· Modified Hoehn and Yahr stage <= 2.5 Untreated patients Generally healthy and ambulatory Patient has given his informed written consent and is capable of following study procedures  Any indication of forms of parkinsonism other than PD Severe resting tremor Presence of either dyskinesia, fluctuations, or loss of postural reflexes· Treatment with L-Dopa, dopamine agonist, amantadine, anticholinergics, catechol-o-methyltransferase (COMT ) inhibitors, selegiline, dopamine receptor antagonists, catecholamine depleters, indirect dopamine agonists or alphamethyldopa Electroconvulsive therapy (ECT) Use of CYP3A4 strong, and moderate inducers or inhibitors Participation in another clinical trial with an investigational drug within two months prior to randomization Dementia, uncontrolled depression, psychotic disorder History of substance-related disorders including alcohol or other substance use disorders Females of child bearing potential
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Parkinson's Disease Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK Brain Bank criteria Current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off' Able to manipulate electronic monitoring bottles and complete questionnaires  Current use of compliance aid such that study participation would be detrimental to patient's adherence Pregnancy or breast feeding Excess alcohol (over 21 units per week for women and 28 units for men) Mini mental state examination of less than 26 Severe depression (Geriatric depression score over 20)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Parkinson Disease Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism) (1) Patients meeting all of the following 1. Patients of at least 20 years of age 2. In or outpatients of either sex. 3. Patients in any stage on the modified Hoehn and Yahr severity scale  Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour Patients with subjective symptoms derived from orthostatic hypotension Patients with hypotension (systolic blood pressure <100 mmHg) Patients with concomitant illness such as severe cardiac, renal, and hepatic disease Patients with a current or past history of epilepsy Pregnant, possibly pregnant, or lactating women Patients receiving any other investigational products or who have received any other investigational product within 6 months of the study Patients who judged incompetent to give consent Others judged by the investigator or co-investigator to be ineligible as subjects
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hepatic Encephalopathy Hepatitis C Liver Cirrhosis Phase A Subject is 18 to 70 years of age, inclusive Subject has cirrhosis due to chronic HCV infection as documented by Subject has evidence of hepatic encephalopathy as evidenced by Neuro-psychometric Testing (Number Connection Test, Trails Test, etc.) Subject is non-azotemic (creatinine <1.5mg/dL) and ambulatory at screening Subject has cirrhosis due to chronic HCV as documented by: pathologic or clinical and radiographic evidence of cirrhosis with a positive HCV RNA PCR level. Phase A  Subject has received active interferon therapy within 2 weeks of enrollment Subject is pregnant or lactating Subject has a life expectancy of less than 100 days Subject has a history of alcohol abuse within 6 months of enrollment Subject has active gastrointestinal bleeding at time of enrollment Subject has used an agent that alters intestinal motility, eg, methadone, cholestyramine, tricyclic antidepressants Subject is unable to take oral medication Subject has used neomycin or other antibiotic within 2 weeks of enrollment or is actively using lactulose at time of enrollment Subject is taking or has hypersensitivity or allergy to rifaximin or rifampin Subject requires long term antibiotic therapy (eg, Lyme Disease, tuberculosis)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Parkinson's Disease Patients must have a clinical diagnosis of probable idiopathic PD Demonstrated response to dopaminergic therapy, defined as demonstrating at least 30% improvement in parkinsonian motor signs, based upon the UPDRS motor examination subscore, following the administration of their dopamine agonist (DA) drug(s) during the screening neurological examination Hoehn and Yahr (H&Y) stage II when OFF medication No contraindications to surgery Age between 50 and 75 years old Available for follow-up for four years Informed Consent: The subject understands the risks, benefits, and alternatives to the study procedures and participation in the study MRI within normal range for age Levodopa or dopamine agonist therapy for greater than six months but less than or equal to four years  Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by features unusual early in the clinical course: Prominent postural instability, freezing phenomena, or hallucinations unrelated to medications in the first 3 years after symptom onset; dementia preceding motor symptoms; supranuclear gaze palsy (other than restriction of upward gaze) or slowing of vertical saccades in the first year; severe, symptomatic dysautonomia unrelated to medications; documentation of a condition known to produce parkinsonism and plausibly connected to the subject's symptoms (such as suitably located focal brain lesions or neuroleptic use within the past 6 months) Uncontrolled medical condition or clinically significant medical disease that would increase the risk of developing pre or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension) Evidence of dementia Major psychiatric disorder Previous brain operation or injury Active participation in another clinical trial for the treatment of PD Patients who have demand cardiac pacemakers or implantable cardioverter defibrillators (ICD's) Patients who have medical conditions that require repeat MRI scans or diathermy treatments Evidence of existing dyskinesias or motor fluctuations
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Parkinson's Disease UK PD Society Brain Bank for the diagnosis of idiopathic PD Patients with stable levodopa-induced dyskinesias present greater than 25% of the day (Unified Parkinson's Disease Rating Scale (UPDRS), item 32, rating > 2) and be moderately to completely disabling (UPDRS item 33, rating > 2) All anti-parkinsonian medications must be stable for at least one month prior to study enrollment  prior surgery for PD Hoehn and Yahr score of 5 when "off" History of nephrolithiasis Renal impairment Liver disease Pregnancy Premenopausal females and males not using adequate contraception Cognitive impairment (Mini Mental State Exam score less than 24) History of glaucoma or seizures Use of other antiepileptic drugs